Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ANAB Stock Forecast 2025-2026
$20.70
Current Price
$634.80M
Market Cap
Buy 9
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to ANAB Price Targets
+175.4%
To High Target of $57.00
+93.2%
To Median Target of $40.00
-13.0%
To Low Target of $18.00
ANAB Price Momentum
+0.4%
1 Week Change
+9.2%
1 Month Change
-1.4%
1 Year Change
+56.3%
Year-to-Date Change
-49.9%
From 52W High of $41.31
+69.5%
From 52W Low of $12.21
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching AnaptysBio (ANAB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ANAB and similar high-potential opportunities.
Latest ANAB Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, ANAB has a bullish consensus with a median price target of $40.00 (ranging from $18.00 to $57.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $20.70, the median forecast implies a 93.2% upside. This outlook is supported by 9 Buy, 3 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ANAB Analyst Ratings
9
Buy
3
Hold
0
Sell
ANAB Price Target Range
Low
$18.00
Average
$40.00
High
$57.00
Current: $20.70
Latest ANAB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ANAB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $42.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $22.00 |
| Feb 13, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $51.00 |
| Feb 7, 2025 | Wedbush | David Nierengarten | Outperform | Maintains | $40.00 |
| Feb 4, 2025 | HC Wainwright & Co. | Emily Bodnar | Neutral | Reiterates | $19.00 |
| Feb 4, 2025 | Wolfe Research | Andy Chen | Outperform | Initiates | $0.00 |
| Dec 19, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $36.00 |
| Dec 18, 2024 | Truist Securities | John Lee | Hold | Maintains | $20.00 |
| Dec 12, 2024 | Guggenheim | Yatin Suneja | Buy | Maintains | $36.00 |
| Dec 12, 2024 | Wells Fargo | Derek Archila | Overweight | Maintains | $40.00 |
| Dec 11, 2024 | HC Wainwright & Co. | Emily Bodnar | Neutral | Downgrade | $0.00 |
| Dec 2, 2024 | BTIG | Julian Harrison | Neutral | Downgrade | $0.00 |
| Nov 12, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $66.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Maintains | $52.00 |
| Oct 31, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $55.00 |
| Oct 30, 2024 | UBS | Eliana Merle | Neutral | Maintains | $33.00 |
| Oct 21, 2024 | Guggenheim | Yatin Suneja | Buy | Maintains | $90.00 |
| Sep 26, 2024 | Wedbush | David Nierengarten | Outperform | Reiterates | $42.00 |
| Aug 15, 2024 | Truist Securities | John Lee | Hold | Maintains | $30.00 |
| Aug 14, 2024 | HC Wainwright & Co. | Emily Bodnar | Buy | Reiterates | $55.00 |
AnaptysBio Inc. (ANAB) Competitors
The following stocks are similar to AnaptysBio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
AnaptysBio Inc. (ANAB) Financial Data
AnaptysBio Inc. has a market capitalization of $634.80M with a P/E ratio of -4.0x. The company generates $91.28M in trailing twelve-month revenue with a -159.1% profit margin.
Revenue growth is +378.8% quarter-over-quarter, while maintaining an operating margin of -22.4% and return on equity of -182.7%.
Valuation Metrics
Market Cap
$634.80M
Enterprise Value
$618.89M
P/E Ratio
-4.0x
PEG Ratio
-3.2x
Price/Sales
7.0x
Growth & Margins
Revenue Growth (YoY)
+378.8%
Gross Margin
N/A
Operating Margin
-22.4%
Net Margin
-159.1%
EPS Growth
+378.8%
Financial Health
Cash/Price Ratio
+60.7%
Current Ratio
9.5x
Debt/Equity
521.3x
ROE
-182.7%
ROA
-15.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
AnaptysBio Inc. (ANAB) Business Model
About AnaptysBio Inc.
What They Do
Develops innovative antibody therapies for diseases.
Business Model
AnaptysBio operates as a clinical-stage biotechnology company that generates revenue primarily through the development of novel antibody therapies targeting unmet medical needs in immuno-oncology and inflammation. The company utilizes its proprietary antibody discovery platform to create humanized monoclonal antibodies, which may lead to partnerships, licensing agreements, and potential product sales once therapies are brought to market.
Additional Information
The company's commitment to research and development positions it as a key player in the biopharmaceutical industry, particularly in the fields of precision medicine and personalized healthcare solutions, aiming to improve patient outcomes for serious medical conditions.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
136
CEO
Mr. Daniel R. Faga
Country
United States
IPO Year
2017
Website
www.anaptysbio.comAnaptysBio Inc. (ANAB) Latest News & Analysis
Latest News
Anaptys Announces Stock Repurchase Plan
1 month ago
Quick Summary
AnaptysBio, Inc. (Nasdaq: ANAB) has authorized a $75 million stock repurchase plan for its common shares, aimed at enhancing shareholder value.
Why It Matters
AnaptysBio's $75M stock repurchase plan signals confidence in its value, potentially boosting share prices and indicating strong cash flow, which can enhance investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AnaptysBio (ANAB) experienced significant trading volume recently, and positive earnings estimate revisions may contribute to potential upward movement in the stock.
Why It Matters
Higher trading volume and positive earnings estimate revisions suggest increased investor interest and potential for stock price appreciation in AnaptysBio (ANAB).
Source: Zacks Investment Research
Market Sentiment:
Positive
Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2 months ago
Quick Summary
AnaptysBio reported positive Phase 2b results for rosnilimab in rheumatoid arthritis, with data due in Q2 2025. They have $420M in cash, extending runway to 2027.
Why It Matters
Positive Phase 2b results for rosnilimab in rheumatoid arthritis suggest strong market potential, enhancing AnaptysBio's value and attracting investor interest amid a competitive landscape.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AnaptysBio, Inc. (ANAB) reported a quarterly loss of $0.72 per share, outperforming the Zacks Consensus Estimate of a loss of $1.61, and improved from a loss of $1.59 per share a year ago.
Why It Matters
AnaptysBio's smaller-than-expected loss signals improved financial performance, potentially boosting investor confidence and affecting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
AnaptysBio, Inc. (Nasdaq: ANAB) will participate in several investor conferences in March 2025, including TD Cowen, Leerink Partners, and Barclays, with live webcasts available online.
Why It Matters
AnaptysBio's participation in key investor conferences signals potential insights into its growth strategy and product pipeline, influencing investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
AnaptysBio (ANAB) shares rose significantly with above-average trading volume, and positive earnings estimate revisions may lead to further price increases soon.
Why It Matters
AnaptysBio's share surge and increased trading volume signal growing investor interest, while positive earnings estimate revisions suggest potential for further price appreciation.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About ANAB Stock
What is AnaptysBio Inc.'s (ANAB) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, AnaptysBio Inc. (ANAB) has a median price target of $40.00. The highest price target is $57.00 and the lowest is $18.00.
Is ANAB stock a good investment in 2025?
According to current analyst ratings, ANAB has 9 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $20.70. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ANAB stock?
Wall Street analysts predict ANAB stock could reach $40.00 in the next 12 months. This represents a 93.2% increase from the current price of $20.70. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is AnaptysBio Inc.'s business model?
AnaptysBio operates as a clinical-stage biotechnology company that generates revenue primarily through the development of novel antibody therapies targeting unmet medical needs in immuno-oncology and inflammation. The company utilizes its proprietary antibody discovery platform to create humanized monoclonal antibodies, which may lead to partnerships, licensing agreements, and potential product sales once therapies are brought to market.
What is the highest forecasted price for ANAB AnaptysBio Inc.?
The highest price target for ANAB is $57.00 from at , which represents a 175.4% increase from the current price of $20.70.
What is the lowest forecasted price for ANAB AnaptysBio Inc.?
The lowest price target for ANAB is $18.00 from at , which represents a -13.0% decrease from the current price of $20.70.
What is the overall ANAB consensus from analysts for AnaptysBio Inc.?
The overall analyst consensus for ANAB is bullish. Out of 23 Wall Street analysts, 9 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $40.00.
How accurate are ANAB stock price projections?
Stock price projections, including those for AnaptysBio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 28, 2025 10:03 AM UTC